Tag Archives: Raju Prasad
William Blair Believes Verve Therapeutics (NASDAQ: VERV) Still Has Room to Grow
In a report released today, Raju Prasad from William Blair maintained a Buy rating on Verve Therapeutics (VERV – Research Report). The company’s shares closed last Wednesday at $70.70, close to its 52-week high of $74.44. According to TipRanks.com, Prasad
Rocket Pharmaceuticals (RCKT) Gets a Buy Rating from William Blair
William Blair analyst Raju Prasad maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) today. The company’s shares closed last Monday at $33.63. According to TipRanks.com, Prasad is a 4-star analyst with an average return of 11.5% and
William Blair Keeps Their Buy Rating on Krystal Biotech (KRYS)
In a report released today, Raju Prasad from William Blair maintained a Buy rating on Krystal Biotech (KRYS – Research Report). The company’s shares closed last Thursday at $71.77. According to TipRanks.com, Prasad is a 5-star analyst with an average
William Blair Thinks PTC Therapeutics’ Stock is Going to Recover
In a report released today, Raju Prasad from William Blair maintained a Buy rating on PTC Therapeutics (PTCT – Research Report). The company’s shares closed last Wednesday at $38.74, close to its 52-week low of $37.12. According to TipRanks.com, Prasad
William Blair Thinks Cellectis SA’s Stock is Going to Recover
In a report released today, Raju Prasad from William Blair maintained a Buy rating on Cellectis SA (CLLS – Research Report). The company’s shares closed last Friday at $15.67, close to its 52-week low of $14.25. According to TipRanks.com, Prasad
William Blair Upgrades Selecta Biosciences (SELB) to Buy
In a report released today, Raju Prasad from William Blair upgraded Selecta Biosciences (SELB – Research Report) to Buy. The company’s shares closed last Thursday at $3.90. According to TipRanks.com, Prasad is a 5-star analyst with an average return of
